Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Renal Solutions' Allient haemodialysis:

This article was originally published in Clinica

Executive Summary

Renal Solutions has received US FDA 510(k) clearance to sell an improved version of its Allient sorbent haemodialysis system for chronic and acute haemodialysis applications. The product, which includes the firm's Sorb and Hisorb series of cartridges, incorporates advanced haemocompatible materials in its Pulsar blood pump component, said the Warrendale, Pennsylvania company. Comprising what the firm describes as a unique, pressure-limited, two-chamber design, the Pulsar pump represents "the first significant step forward in dialysis blood pump design in several decades", Renal Solutions claimed. The firm added that its Allient product opened new treatment options, by virtue of its ability to provide short, standard or extended duration haemodialysis therapy using just 1 and 0.5 gallons of ordinary drinking water.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT052031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel